Universität zu Köln

Laible, Mark, Schlombs, Kornelia, Kaiser, Katharina, Veltrup, Elke, Herlein, Stefanie, Lakis, Sotiris, Stoehr, Robert, Eidt, Sebastian, Hartmann, Arndt, Wirtz, Ralph M. and Sahin, Ugur ORCID: 0000-0003-0363-1564 (2016). Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer, 16. LONDON: BMC. ISSN 1471-2407

Full text not available from this repository.

Abstract

Background: MammaTyper is a novel CE-marked in vitro diagnostic RT-qPCR assay which assigns routinely processed breast cancer specimens into the molecular subtypes Luminal A-like, Luminal B-like (HER2 positive or negative), HER2 positive (non-luminal) and Triple negative (ductal) according to the mRNA expression of ERBB2, ESR1, PGR and MKI67 and the St Gallen consensus surrogate clinical definition. Until now and regarding formalin-fixed, paraffin-embedded material (FFPE), this has been a task mostly accomplished by immunohistochemistry (IHC). However the discrepancy rates of IHC for the four breast cancer biomarkers are frequently under debate, especially for Ki-67 which carries the highest degree of inter-and even intra-observer variability. Herein we describe a series of studies in FFPE specimens which aim to fully validate the analytical performance of the MammaTyper assay, including the site to site reproducibility of the individual marker measurements. Methods: Tumor RNA was extracted with the novel RNXtract RNA extraction kit. Synthetic RNA was used to assess the sensitivity of the RNXtract kit. DNA and RNA specific qPCR assays were used so as to determine analyte specificity of RNXtract. For the assessment of limit of blank, limit of detection, analytical measurement range and PCR efficiency of the MammaTyper kit serial dilutions of samples were used. Analytical precision studies of MammaTyper were built around two different real time PCR platforms and involved breast tumor samples belonging to different subtypes analyzed across multiple sites and under various stipulated conditions. The MammaTyper assay robustness was tested against RNA input variations, alternative extraction methods and tumor cell content. Results: Individual assays were linear up to at least 32.33 and 33.56 Cqs (quantification cycles) for the two qPCR platforms tested. PCR efficiency ranged from 99 to 109 %. In qPCR platform 1, estimates for assay specific inter-site standard deviations (SD) were between 0.14 and 0.20 Cqs accompanied by >94 % concordant single marker assignments for all four markers. In platform 2, the inter-site SD estimates were between 0.40 and 0.66 Cqs while the concordance for single marker assignments was >94 % for all four markers. The agreement reached between the two qPCR systems located in one site was 100 % for ERBB2, 96.9 % for ESR1, 97.2 % for PGR and 98.6 % for MKI67. RT-qPCR for individual markers was stable up to a 64-fold dilution for a typical clinical sample. There was no change in assay performance detected at the level of individual markers or subtypes after using different RNA isolation methods. The presence of up to 80 % of surrounding non-tumor tissue including in situ carcinoma did not affect the assay output. Sixteen out of 20 RNXtract eluates yielded more than 50 ng/mu l of RNA (average RNA output: 233 ng/mu l), whereas DNA contamination per sample was restricted to less than 15 ng/mu l. Median recovery rate of RNA extraction was 91.0 %. Conclusions: In this study the performance characteristics of MammaTyper were successfully validated. The various sources of analytical perturbations resulted in negligible variations in individual marker assessments. Therefore, MammaTyper may serve as a technical improvement to current standards for decentralized FFPE-based routine assessment of the commonly used breast cancer biomarkers and for molecular subtyping of breast cancer specimens.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Laible, Mark UNSPECIFIED UNSPECIFIED UNSPECIFIED Schlombs, Kornelia UNSPECIFIED UNSPECIFIED UNSPECIFIED Kaiser, Katharina UNSPECIFIED UNSPECIFIED UNSPECIFIED Veltrup, Elke UNSPECIFIED UNSPECIFIED UNSPECIFIED Herlein, Stefanie UNSPECIFIED UNSPECIFIED UNSPECIFIED Lakis, Sotiris UNSPECIFIED UNSPECIFIED UNSPECIFIED Stoehr, Robert UNSPECIFIED UNSPECIFIED UNSPECIFIED Eidt, Sebastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Hartmann, Arndt UNSPECIFIED UNSPECIFIED UNSPECIFIED Wirtz, Ralph M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Sahin, Ugur UNSPECIFIED orcid.org/0000-0003-0363-1564 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-270078
DOI:	10.1186/s12885-016-2476-x
Journal or Publication Title:	BMC Cancer
Volume:	16
Date:	2016
Publisher:	BMC
Place of Publication:	LONDON
ISSN:	1471-2407
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PATHOLOGISTS GUIDELINE RECOMMENDATIONS; INTERNATIONAL EXPERT CONSENSUS; AMERICAN-SOCIETY; HER2 STATUS; CLINICAL ONCOLOGY/COLLEGE; LABORATORY COMPLIANCE; SITU HYBRIDIZATION; PRIMARY THERAPY; KI67; EXPRESSION Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/27007